rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2007-66-71rsp-2190Research ArticleЛечение ревматических заболеванийTreatment of rheumatic diseasesПрименение хондопротектора пиаскледин ® в терапии остеоартроза у больных подагройAdministration of chondroprotector piascledine in the treatment of secondary osteoarthritis in patients with goutЕлисеевМ. С.EliseevM. S.

Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-34-29

БарсковаВ. Г.BarskovaV. G.

Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-34-29

НасоновЕ. Л.NasonovE. L.

Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-34-29

ГУ Институт ревматологии РАМН, МоскваRussian Federation2007120520164546671Copyright © Елисеев М.С., Барскова В.Г., Насонов Е.Л., 20162016Елисеев М.С., Барскова В.Г., Насонов Е.Л.Eliseev M.S., Barskova V.G., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2190Цель

Цель. Изучить клиническую эффективность и безопасность препарата Пиаскледин® при лечении остеоартроза (OA) у больных подагрой.

Материал и методы

Материал и методы. Включены 30 больных подагрой, сочетающейся с ОА. В течение 2-х мес больные принимали пиаскледин 300 мг/сут. Критерии включения: диагноз подагра (критерии Wallace S.), диагноз ОА (критерии ACR), возраст >35 лет. Критерии исключения: почечная и печеночная недостаточность, тяжелые инфекции, детородный возраст у женщин, прием других хондропротекторов. Осмотр, лабораторные исследования проводились до и через 2 мес после приема пиаскледина.

Результаты

Результаты. Выраженности боли в суставах по ВАШ через 2 мес приема пиаскледина уменьшилась как в покое (р<0,01), так и при движении (р<0,05). Побочных эффектов, послуживших причиной отмены препарата, зафиксировано не было. Сывороточный уровень мочевой кислоты, показатели липидного и углеводного обменов, функции печени и почек существенно не отличались от исходных.

Заключение

Заключение. Применение пиаскледина у больных подагрой в сочетании с ОА не влияет на сывороточный уровень мочевой кислоты, характеризуется безопасностью, хорошей переносимостью и эффективностью в отношении выраженности болевого синдрома.

Objective

Objective. To study clinical efficacy and safety of piascledine in the treatment of osteoarthritis (OA) in pts with gout.

Material and methods

Material and methods. 30 pts older than 35 years with gout and concomitant OA were included. During 2 months they received piascledine 300 mg/day. All pts fulfilled Wallace S. criteria for gout and ACR criteria for OA. Exclusion criteria: renal and hepatic failure,severe infections, childbearing potential female, administration of other chondroprotectors. Clinical and laboratory examination was performed before and after 2 months of treatment with piascledine.

Results

Results. After 2 months of treatment pain on VAS decreased at rest (p<0,01) and at movement (p<0,05). There were no adverse events leading to withdrawal of the drug. Uric acid serum level, measures of lipid and carbohydrate metabolism, renal and hepatic function did not significantly differ from baseline.

Conclusion

Conclusion. Piascledine administration in gout pts with OA is safe, effectively decrease pain and do not influence serum level of uric acid.

подаграостеоартрозпиасклединgoutosteoarthritispiascledineReferencesНасонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практич. ревматол., 2004, 1, 5-7Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практич. ревматол., 2004, 1, 5-7Li-Yu J., Clauburne G., Sieck M. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol., 2001, 28, 577-580Li-Yu J., Clauburne G., Sieck M. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol., 2001, 28, 577-580Pascual E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of patients with untreared gout. Arthr. Rheum., 1991, 42 (2), 141-145Pascual E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of patients with untreared gout. Arthr. Rheum., 1991, 42 (2), 141-145Pascual E., Battle-Gualda E., Martinez A. et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med., 1999, 131, 758-759Pascual E., Battle-Gualda E., Martinez A. et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med., 1999, 131, 758-759Di Giovine F.S., Malawista S.E., Thornton E., Duff G.W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. Clin Invest., 1991, 87(4), 1375–1381Di Giovine F.S., Malawista S.E., Thornton E., Duff G.W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. Clin Invest., 1991, 87(4), 1375–1381Inokuchi T., Moriwaki Y., Tsutsui H. et al. Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 2006, 33(1), 21-27Inokuchi T., Moriwaki Y., Tsutsui H. et al. Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 2006, 33(1), 21-27Martinon F., Petrilli V., Mayor A. et al. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081), 237-241Martinon F., Petrilli V., Mayor A. et al. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature, 2006, 440(7081), 237-241Schweyer S., Hemmerlein B., Radzun H.J., Fayyazi A. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows. Arch. 2000, 437, 534-539Schweyer S., Hemmerlein B., Radzun H.J., Fayyazi A. Continuous recruitment, co-expression of tumour necrosis factor-alpha and matrix metalloproteinases, and apoptosis of macrophages in gout tophi. Virchows. Arch. 2000, 437, 534-539Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions. Clin. Cornestone, 1999, 2, 17-31Khaodhiar L., McCowen K.C., Blackburn G.L. Obesity and comorbid conditions. Clin. Cornestone, 1999, 2, 17-31Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch. Intern. Med, 2005, 165, 742-748Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch. Intern. Med, 2005, 165, 742-748Б арскова В.Г. Метаболический синдром и кардиоваскулярные нарушения при подагре. Дисс. д.м.н., М., 2006, 291Б арскова В.Г. Метаболический синдром и кардиоваскулярные нарушения при подагре. Дисс. д.м.н., М., 2006, 291Gutman A.B. Gout, in Beeson PB, McDermott W (eds): Textbook of Medicine (ed 12). Philadelphia, Saunders, 1967, 1238Gutman A.B. Gout, in Beeson PB, McDermott W (eds): Textbook of Medicine (ed 12). Philadelphia, Saunders, 1967, 1238Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York, 1976, 512Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York, 1976, 512Maheu E., Coste P. Piascledine 300: Clinical apdate. 1998, 1-26Maheu E., Coste P. Piascledine 300: Clinical apdate. 1998, 1-26Blotman F., Maheu E., Wulwic A., et al. Efficasy and safety of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Rev. Rhum. (Engl. Ed.), 1997, 64(12), 825-834Blotman F., Maheu E., Wulwic A., et al. Efficasy and safety of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Rev. Rhum. (Engl. Ed.), 1997, 64(12), 825-834Maheu E., Mazieres B., Valat J.P. et. al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthr. Rheum., 1998, 41(1), 81-91Maheu E., Mazieres B., Valat J.P. et. al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthr. Rheum., 1998, 41(1), 81-91Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Nrials (ESCISIT). Ann. Rheum. Dis., 2003, 62, 1145-1155Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Nrials (ESCISIT). Ann. Rheum. Dis., 2003, 62, 1145-1155Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. Rheum., 1977, 20, 895-900Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. Rheum., 1977, 20, 895-900Altman R., Asch E., Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Ibid., 1986, 29(8), 1039-1045.Altman R., Asch E., Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Ibid., 1986, 29(8), 1039-1045.Altman R., Alarson G., Appelrouth D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Rheum., 1991, 34, 505-514Altman R., Alarson G., Appelrouth D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Rheum., 1991, 34, 505-514Huskisson E.S. Measurement of a painful syndrome. Lancet, 1974, 2, 1127-1131Huskisson E.S. Measurement of a painful syndrome. Lancet, 1974, 2, 1127-1131Martel-Pelletier J., McCollum R., DiBattista J. et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: identification as the type I receptor and analysis of binding kinetics and biologic function. Arthr. Rheum., 1992, 35, 530-540Martel-Pelletier J., McCollum R., DiBattista J. et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: identification as the type I receptor and analysis of binding kinetics and biologic function. Arthr. Rheum., 1992, 35, 530-540Henrotin Y.E., Labasse A.H., Jaspar J.M. et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglaldin E2 production by human articular chondrocytes. Arthr. Rheum., 1998, 17, 31-39Henrotin Y.E., Labasse A.H., Jaspar J.M. et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglaldin E2 production by human articular chondrocytes. Arthr. Rheum., 1998, 17, 31-39So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthr. Res. Ther., 2007, 9, R28So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthr. Res. Ther., 2007, 9, R28Елисеев М.С., Барскова В.Г., Насонова В.А. Клиническое значение метаболического синдрома при подагре. Клинич. геронтология, 2006, 2, 29-33Елисеев М.С., Барскова В.Г., Насонова В.А. Клиническое значение метаболического синдрома при подагре. Клинич. геронтология, 2006, 2, 29-33Choi H.K., Atkinson K., Karlson E.W. et al. Purinerich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med., 2004, 350 , 1093- 1103Choi H.K., Atkinson K., Karlson E.W. et al. Purinerich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med., 2004, 350 , 1093- 1103

The authors declare that there are no conflicts of interest present.